Research library

D

grade

There is no conclusive evidence linking semaglutide to increased or decreased suicidality, and findings are highly imprecise.

Completed suicide: pooled OR 1.56 (95% CrI 0.55–4.67), P(OR > 1) = 80.6%, n=17,086 semaglutide vs 15,304 placebo.

summary

B

grade

Lower doses of compounded semaglutide may achieve significant weight loss when combined with behavioral programs, reaching 91% of the weight loss seen with higher doses in 16 weeks.

At 16 weeks, NMGP users lost 8.3% of their baseline weight.

summary

B

grade

Lower doses of compounded semaglutide may lead to fewer side effects compared to higher doses in the first 16 weeks of treatment.

34% lower relative odds of reporting GI side effects by week 16, p=0.001, n=2,481 per group.

summary

B

grade

Elevated body mass index (BMI) is a causal risk factor for progression to end-stage renal disease in patients with type 2 diabetes mellitus, while higher hematocrit appears protective.

AUC of the logistic regression-based nomogram was 0.88 (95% CI: 0.85-0.91).

summary

B

grade

The ZIP approach allows for quick, patient-centered discussions in primary care, with patients reporting high satisfaction in shared decision-making.

Mean SDM-Q-9 score was 90.9 out of 100.

summary

B

grade

GLP-1 receptor agonists like semaglutide and tirzepatide do not appear to increase the risk of oral health issues broadly, but dry mouth may be a concern associated with weight loss.

8.69% of GLP-1 users developed at least one newly documented oral-health condition.

summary

C

grade

Oral semaglutide may help preserve islet structure and function in type 2 diabetic rats, but further research is needed to confirm these effects in humans.

P < 0.05 for islet size, β-cell mass, and insulin immunoreactivity.

summary

B

grade

The study suggests that a two-class biomarker-defined phenotype structure may better reflect patient heterogeneity than a single physiological reserve score.

KMO = 0.485

summary

D

grade

Semaglutide has the highest reported association with impaired gastric emptying among GLP-1 receptor agonists, but this study does not claim causation.

PRR 88.7, 95% CI 85.1–92.4; 3,052 of 82,911 reports

summary

D

grade

Semaglutide-based products show the highest reporting ratios for impaired gastric emptying among GLP-1 receptor agonists, but further studies are needed to understand the clinical significance.

Ozempic PRR 109.1; Rybelsus 66.4

summary

B

grade

Weight regain during semaglutide or tirzepatide treatment is linked to increased inflammation and higher cardiovascular event rates, highlighting the need for careful monitoring.

12.9 vs 9.6 per 1,000 person-years for nonfatal MACE during regained time vs maintained-loss time, adjusted RR: 1.43 (95% CI 1.22–1.67).

summary

D

grade

Hepatotoxicity from turmeric and curcuminoids is rare, but caution is advised, especially for those with liver issues. Users should consult healthcare practitioners if symptoms arise.

Not reported in abstract.

summary

B

grade

Semaglutide may help reduce hunger pain in people with schizophrenia on antipsychotics, but attention to potential negative effects is necessary.

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

A

grade

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

A

grade

Not reported in abstract.

summary

D

grade

Not reported in abstract.

summary

D

grade

Multimodal strategies for obesity management, including GLP-1 therapies and surgical interventions, may lead to greater weight loss than single approaches, but the evidence is largely observational and requires further validation.

Not reported in abstract.

summary

B

grade

Semaglutide is associated with a higher rate of basal insulin discontinuation compared to SGLT2 inhibitors, while tirzepatide shows greater insulin dose reduction and glycemic improvement.

27.8% discontinued basal insulin with semaglutide vs 22.2% with SGLT2-i at 24 months, sHR 1.26, 95% CI 1.05–1.52, Gray P=0.013

summary

B

grade

Tirzepatide may be associated with lower risks of major cardiovascular events compared to semaglutide in adults with obesity without type 2 diabetes, but further randomized trials are needed to confirm these findings.

HR 0.80; 95% CI 0.69–0.92 for MACE at 12 months.

summary

D

grade

GLP-1 receptor agonists, including semaglutide, are associated with significant neuropsychiatric safety signals, warranting careful monitoring in clinical practice.

ROR 3.94; 95%CI 3.42-4.54 for muscle atrophy with semaglutide.

summary

C

grade

Semaglutide activates specific neuronal systems and increases acetylcholine in the rat hippocampus, suggesting a potential mechanism for cognitive effects.

Semaglutide acutely increases acetylcholine efflux in the ventral hippocampus of conscious and freely moving rats.

summary